CD47 and Anaplastic (Malignant) Meningioma: It is believed that with the development of targeting technology and drug targeting carriers, anti-CD47 drugs will be targeted and quantitatively acted on local tumor tissues, especially tumors such as malignant meningioma, so as to achieve the effective cure of tumors.